Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Bilal Siddiqui, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives: * To evaluate the safety and tolerability of REGN5678 (PSMAxCD28 bispecific antibody) plus cemiplimab (anti-PD-1) in patients with mCRPC. * To determine the maximum tolerated dose or potential recommended phase II dose (RP2D) of REGN5678 (PSMAxCD28 bispecific antibody) plus cemiplimab (anti-PD-1) in patients with mCRPC Secondary Objectives: * To evaluate efficacy of REGN5678 plus cemiplimab in patients with mCRPC. * To characterize the PK of REGN5678 alone and in combination with cemiplimab * To assess the immunogenicity of REGN5678 and cemiplimab. Exploratory Objective: • To evaluate immune responses in the prostate TME and peripheral blood after treatment with REGN5678 plus cemiplimab as compared to pre-treatment samples.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted